374 related articles for article (PubMed ID: 32074774)
1. [Analysis of magnetic resonance imaging characteristics in Chinese patients with myelin oligodendrocyte glycoprotein antibody associated disorders].
Liu CX; Chen C; Zhong XN; Wang YG; Yang Y; Li R; Sun XB; Fang L; Peng LS; Qiu W
Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):328-333. PubMed ID: 32074774
[No Abstract] [Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis].
Zhangbao BJZ; Zhou L; Wang L; Huang WJ; Zhao CB; Lu JH; Quan C
Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):334-338. PubMed ID: 32074775
[No Abstract] [Full Text] [Related]
4. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
6. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children.
Tantsis EM; Prelog K; Alper G; Benson L; Gorman M; Lim M; Mohammad SS; Ramanathan S; Brilot F; Dale RC;
Dev Med Child Neurol; 2019 Sep; 61(9):1108-1116. PubMed ID: 30537075
[TBL] [Abstract][Full Text] [Related]
9. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
10. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study.
Chen C; Liu C; Fang L; Zou Y; Ruan H; Wang Y; Cui C; Sun X; Peng L; Qiu W
J Neurol Sci; 2019 Oct; 405():116430. PubMed ID: 31465985
[TBL] [Abstract][Full Text] [Related]
11. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
13. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.
Zhao Y; Tan S; Chan TCY; Xu Q; Zhao J; Teng D; Fu H; Wei S
Br J Ophthalmol; 2018 Oct; 102(10):1372-1377. PubMed ID: 29363529
[TBL] [Abstract][Full Text] [Related]
15. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
16. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
18. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
[No Abstract] [Full Text] [Related]
20. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
Cortese R; Battaglini M; Prados F; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Wuerfel J; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Callegaro D; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira A; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Proebstel AK; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Carmisciano L; Sormani MP; Barkhof F; De Stefano N; Ciccarelli O;
Brain; 2023 Jun; 146(6):2489-2501. PubMed ID: 36515653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]